These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 15025846)

  • 21. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
    Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H
    J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
    Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
    J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
    Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
    J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study.
    Ioachimescu AG; Brennan DM; Hoar BM; Hazen SL; Hoogwerf BJ
    Arthritis Rheum; 2008 Feb; 58(2):623-30. PubMed ID: 18240236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered uric acid levels and disease states.
    Kutzing MK; Firestein BL
    J Pharmacol Exp Ther; 2008 Jan; 324(1):1-7. PubMed ID: 17890445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hyperuricemia in hypertension: any clinical implication?].
    Deléaval P; Burnier M
    Rev Med Suisse; 2005 Sep; 1(32):2072-4, 2077-9. PubMed ID: 16238227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
    Zhu X; Chen J; Han F; Cheng M; Xu L; Zhang L; Ding X; Le Y
    Transplant Proc; 2009 Nov; 41(9):3736-42. PubMed ID: 19917377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uric acid: bystander or culprit in hypertension and progressive renal disease?
    Menè P; Punzo G
    J Hypertens; 2008 Nov; 26(11):2085-92. PubMed ID: 18854744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML; Iversen EK; Høieggen A; Flaa A; Os I; Kjeldsen SE; Olsen MH; Chattopadhyay A; Hille DA; Lyle PA; Devereux RB; Dahlöf B
    Am J Cardiol; 2007 Sep; 100(5):855-9. PubMed ID: 17719333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
    Olsen MH; Wachtell K; Nielsen OW; Hall C; Wergeland R; Ibsen H; Kjeldsen SE; Devereux RB; Dahlöf B; Hildebrandt PR
    J Hypertens; 2006 Aug; 24(8):1531-9. PubMed ID: 16877955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The paradoxical relationship between serum uric acid and cardiovascular disease.
    Lippi G; Montagnana M; Franchini M; Favaloro EJ; Targher G
    Clin Chim Acta; 2008 Jun; 392(1-2):1-7. PubMed ID: 18348869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery.
    Dunkelgrun M; Welten GM; Goei D; Winkel TA; Schouten O; van Domburg RT; van Gestel YR; Flu WJ; Hoeks SE; Bax JJ; Poldermans D
    Am J Cardiol; 2008 Oct; 102(7):797-801. PubMed ID: 18805100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hyperuricemia].
    Chizyński K; Rózycka M
    Pol Merkur Lekarski; 2005 Nov; 19(113):693-6. PubMed ID: 16498814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B; Burke TA; Krobot K; Carides GW; Edelman JM; Devereux RB; Diener HC
    J Hum Hypertens; 2004 Jun; 18(6):367-73. PubMed ID: 15029217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia.
    Lin KC; Tsao HM; Chen CH; Chou P
    J Rheumatol; 2004 Jun; 31(6):1152-8. PubMed ID: 15170929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
    Khan M; Khan RA; Islam F; Laghari J; Jamali SN
    Pak J Pharm Sci; 2011 Oct; 24(4):583-7. PubMed ID: 21959825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.